pHGGs amplified in NMYC, PDGFRA and EGFR may arise in children of any age and represent distinct molecular sub-types associated with significantly different behavior: MYCN-amplified gliomas show the poorest prognosis; PDGFRA-amplified gliomas, designated as RTK1 pHGGs, show a better prognosis; and the EGFR-amplified gliomas, designated RTK2 pHGGs, show an intermediate prognosis between the previous two [22]. The gene discussed is MYCN; the disease is central nervous system cancer.